These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27035535)

  • 21. Sustained antidepressant response to ketamine.
    Atigari OV; Healy D
    BMJ Case Rep; 2013 Aug; 2013():. PubMed ID: 23960151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ketamine and the next generation of antidepressants with a rapid onset of action.
    Machado-Vieira R; Salvadore G; Diazgranados N; Zarate CA
    Pharmacol Ther; 2009 Aug; 123(2):143-50. PubMed ID: 19397926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood D-serine levels as a predictive biomarker for the rapid antidepressant effects of the NMDA receptor antagonist ketamine.
    Hashimoto K
    Psychopharmacology (Berl); 2014 Oct; 231(20):4081-2. PubMed ID: 25189793
    [No Abstract]   [Full Text] [Related]  

  • 24. Evolving Issues in the Treatment of Depression.
    Köhler-Forsberg O; Cusin C; Nierenberg AA
    JAMA; 2019 Jun; 321(24):2401-2402. PubMed ID: 31125042
    [No Abstract]   [Full Text] [Related]  

  • 25. Comments on "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606 in patients with treatment-refractory major depressive disorder".
    Hashimoto K
    J Clin Psychopharmacol; 2009 Aug; 29(4):411-2; author reply 412. PubMed ID: 19593196
    [No Abstract]   [Full Text] [Related]  

  • 26. Antidepressant effects of ketamine in depressed patients.
    Berman RM; Cappiello A; Anand A; Oren DA; Heninger GR; Charney DS; Krystal JH
    Biol Psychiatry; 2000 Feb; 47(4):351-4. PubMed ID: 10686270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of ketamine vs. ECT in major depressive disorder: need for ECT standard dosing and duration parameters.
    Campion P
    Psychiatry Res; 2015 Jan; 225(1-2):216. PubMed ID: 25511507
    [No Abstract]   [Full Text] [Related]  

  • 28. Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole.
    Owen RT
    Drugs Today (Barc); 2012 Jul; 48(7):469-78. PubMed ID: 22844658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Speed of response to electroconvulsive therapy compared with ketamine.
    Kellner CH; ; Lisanby SH; Weiner R; Prudic J; Rudorfer MV; Young RC; Petrides G; McCall WV; Husain M; Greenberg RM; Knapp RG
    Psychiatry Res; 2015 Jan; 225(1-2):215. PubMed ID: 25511506
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive
    Witkin JM; Mitchell SN; Wafford KA; Carter G; Gilmour G; Li J; Eastwood BJ; Overshiner C; Li X; Rorick-Kehn L; Rasmussen K; Anderson WH; Nikolayev A; Tolstikov VV; Kuo MS; Catlow JT; Li R; Smith SC; Mitch CH; Ornstein PL; Swanson S; Monn JA
    J Pharmacol Exp Ther; 2017 Apr; 361(1):68-86. PubMed ID: 28138040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation.
    Denk MC; Rewerts C; Holsboer F; Erhardt-Lehmann A; Turck CW
    Am J Psychiatry; 2011 Jul; 168(7):751-2. PubMed ID: 21724677
    [No Abstract]   [Full Text] [Related]  

  • 32. Investigational drugs for treating major depressive disorder.
    Dhir A
    Expert Opin Investig Drugs; 2017 Jan; 26(1):9-24. PubMed ID: 27960559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How does ketamine elicit a rapid antidepressant response?
    Kavalali ET; Monteggia LM
    Curr Opin Pharmacol; 2015 Feb; 20():35-9. PubMed ID: 25462290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate.
    Downey D; Dutta A; McKie S; Dawson GR; Dourish CT; Craig K; Smith MA; McCarthy DJ; Harmer CJ; Goodwin GM; Williams S; Deakin JF
    Eur Neuropsychopharmacol; 2016 Jun; 26(6):994-1003. PubMed ID: 27133029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The complexities of depression.
    Strakowski SM
    Curr Psychiatry Rep; 2012 Dec; 14(6):608-9. PubMed ID: 23011786
    [No Abstract]   [Full Text] [Related]  

  • 36. The rapid-onset antidepressant effect of ketamine: More surprises?
    Raffa RB; Pergolizzi JV; Taylor R;
    J Clin Pharm Ther; 2018 Apr; 43(2):308-311. PubMed ID: 29178131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ketamine and phencyclidine: the good, the bad and the unexpected.
    Lodge D; Mercier MS
    Br J Pharmacol; 2015 Sep; 172(17):4254-76. PubMed ID: 26075331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions.
    Correll GE; Futter GE
    Pain Med; 2006; 7(1):92-5. PubMed ID: 16533209
    [No Abstract]   [Full Text] [Related]  

  • 39. [Ketamine for treatment of depression?].
    Vinberg M
    Ugeskr Laeger; 2013 Sep; 175(37):2089. PubMed ID: 24011202
    [No Abstract]   [Full Text] [Related]  

  • 40. Intravenous ketamine for treatment-resistant major depressive disorder.
    Covvey JR; Crawford AN; Lowe DK
    Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.